Schwab Network on $HIMS

Channel profile →Sources cited by the channel: BFA and JP Morgan, Baird, Bank of America, Barclays, Berenberg, Bernstein, Bernstein, with a Jefferies target cut noted, Bilal Little, Bird (analyst firm), CEO, CEO Joe Dominguez, Caner, Citi, Citigroup, Citizens, Daiwa, Dan Deming and Michael Monahan, Dan Ies; Morgan Stanley, Dan Ives, Dan Ives and unnamed analysts, Deutsche Bank, Erit Research, Evercore ISI, Evercore ISI; Dan Ives, Goldman Sachs, JP Morgan Chase, JPMorgan, JPMorgan Chase, James Demerard of Wall Street Research, Jefferies, Jefferies, UBS and Citigroup, Jensen Huang; Dan Ives, KeyBank, Loop Capital, Mattie Natsson, Michael Saylor, Milius (analyst), Morgan Stanley, Northrop, Oppenheimer, Oppenheimer, Freedom Broker, Oracle, PFA analysts, Quantum CEO, RBC, Reddit CEO, Rothschild Redburn, SK Hynix, Seth, Tim Bigham, Tim and KG, Truist, UBS, Wall Street Journal, Wedbush, Wells Fargo, analysts, the street3 entries

Schwab Network has discussed $HIMS in 3 videos since 2026-09-18.

2026-11-18
“Wednesday's Final Takeaways: Gold at 52-Week Lows, Housing Market Mixed”
AI summary · HIMS launched Peptides Plus with five combination therapies, which could draw new customers beyond traditional telehealth and add recurring revenue amid rising peptide demand, but none of the initial treatments is FDA-approved and HIMS says safety, effectiveness and dosing are still uncertain; regulatory and scientific risk could materially threaten its growth plans.

Hims&Hers may have missed out on the " hot peptide summer," but there may be a " hot peptide winter" coming, as it launches its new "Peptides Plus" platform offering five combination therapies targeting everything from energy and recovery to cellular health.

This move comes at a time when demand for peptides is increasing, but there is a major obstacle here . None of the initial treatments are approved by the Food and Drug Administration (FDA), and the company itself acknowledges that there is still much to learn about their safety, effectiveness, and appropriate dosages .

2026-11-10
“HIMS Earnings Stumble on Double Miss, Guidance Becomes New Focus”
AI summary · After a surprise loss, revenue and subscriber misses and below-consensus guidance, HIMS fell 13.5% to about $19, down almost 40% year to date. The speaker expects it to settle near here with $20 as major support, selling a December out-of-the-money put spread; he sees continued but slower growth, peptide benefits fading and double-digit growth possibly over, while still a solid company.

Let's focus on the chart for Hims and Hers. Shares are under pressure after the healthcare company swung to a surprised loss for the quarter and narrowed its fullear sales outlook.

So here is a look at what we're seeing on the one year. It's come off quite considerably. We're down about 13.5% trading at $19 and change on him and hers. So this is the focus of the morning trade.

2026-09-18Bullish
40% of U.S. Adults to Use GLP-1s? Raul Shah on LLY, NVO & Weight Loss "Mania"
Subscribe or start a trial to unlock this step
1 earlier entry need a subscription
The latest 2 are free to read. Earlier entries keep their date and direction; the text unlocks with a subscription.
Subscribe to read all 1 earlier take